UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36582 Altamira Therapeutics Ltd. (Exact name of registrant as specified in its charter) Clarendon House, 2 Church Street Hamilton HM 11, Bermuda (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or F ...

Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q4 2022 Earnings Conference Call May 16, 2023 8:00 AM ET Company Participants Thomas Meyer - Founder, Chairman and Chief Executive Officer Covadonga Pañeda - Chief Operating Officer Conference Call Participants Operator Good morning, and welcome to the Altamira Therapeutics 2022 Results Conference Call. On today’s call are Thomas Meyer, Altamira’s Founder, Chairman and Chief Executive Officer; and Covadonga Pañeda, Altamira’s Chief Operating Officer. Earlier today, A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ALTAMIRA THERAPEUTICS LTD. (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ OR ☐ SHEL ...

HAMILTON, BERMUDA -- May 16, 2023 -- Altamira Therapeutics Ltd. (Nasdaq:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs, today provided a business update and reported its full year 2022 financial results ended December 31, 2022. Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial Results "We continue to make good progress on our journey to become a leading provider of innovative RNA delivery technology," stated Thomas Meyer, Altamira Therapeut ...

Exhibit 99.1 Unaudited Condensed Consolidated Interim Financial Statements as of June 30, 2022 and December 31, 2021 and for the Six Months Ended June 30, 2022 and 2021 | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------|-------| | | | | Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income or Loss | 2 | | Condensed Consolidated Interim Statement of Financial Position | 3 | | Condense ...

Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q4 2021 Earnings Conference Call April 12, 2022 8:00 AM ET Company Participants Thomas Meyer - Chief Executive Officer Marcel Gremaud - Chief Financial Officer Conference Call Participants Operator Good morning and welcome to Altamira Therapeutics Conference Call. On today's call are Thomas Meyer, Altamira Therapeutics' Founder, Chairman and Chief Executive Officer; and Marcel Gremaud, Altamira Therapeutics' Chief Financial Officer, who will present the company's fin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, par value CHF 0.01 per share CYTO The Nasdaq Stock Market LLC FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT ...

Targeting important unmet medical needs Corporate Presentation September 2021 Forward-Looking Statements This presentation may contain statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' (formerly Auris Medical) strategies or expect ...

Company Presentation 2021 LD Micro Invitational XI – June 9, 2021 Forward-looking Statements This presentation may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Auris Medical's strategies or expectations. In s ...

Exhibit 99.1 Auris Medical Provides Business Update and Reports Second Half and Full Year 2020 Financial Results ● Clinical evaluation of AM-301 nasal spray in allergen protection progressing ● Launch of AM-301 expected in selected markets towards the end of second quarter 2021 ● Phase 2 trial with AM-125 in acute vertigo expected to complete enrollment in third quarter 2021 ● Equity and cash position significantly strengthened ● Strategy review ongoing Hamilton, Bermuda, March 31, 2021 – Auris Medical Hold ...